ARTICLE | Company News
SafeScience, Elan in cancer deal
June 14, 2001 7:00 AM UTC
The companies will form a venture to develop SAFS's GBC-590 carbohydrate lectin inhibitor for cancer. Under the agreement, SAFS will have access to ELN's drug delivery technology to develop an oral fo...